New treatment option shows promise for severe hypertrophic cardiomyopathy in children
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...
Medindia6h
Trametinib: Personalized Treatment for Pediatric Hypertrophic Cardiomyopathy
Discover Trametinib as a promising treatment for severe hypertrophic cardiomyopathy in children with RASopathies.
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...